223

Metformin hydrochloride

223 Publications Verification

Cat. No.: HY-17471A

CAS No.: 1115-70-4

Synonyms: 1,1-Dimethylbiguanide hydrochloride

Target:

AMPK Autophagy Mitophagy Apoptosis mTOR

Research Areas:

Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

223

Metformin

223 Publications Verification

Cat. No.: HY-B0627

CAS No.: 657-24-9

Synonyms: 1,1-Dimethylbiguanide

Target:

AMPK Autophagy Mitophagy Apoptosis mTOR

Research Areas:

Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

109

Insulin (human)

109 Cited Publications

Cat. No.: HY-P0035

CAS No.: 11061-68-0

Target:

Insulin Receptor

Research Areas:

Metabolic Disease Endocrinology

Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

109

Insulin solution (human)

109 Cited Publications

Cat. No.: HY-P0035A

CAS No.: 11061-68-0

Target:

Insulin Receptor

Research Areas:

Metabolic Disease

Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4

72 Cited Publications

Cat. No.: HY-13443

CAS No.: 141758-74-9

Purity: 99.95%

Synonyms: Exenatide

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4 acetate

72 Cited Publications

Cat. No.: HY-13443A

CAS No.: 914454-01-6

Purity: 99.91%

Synonyms: Exenatide acetate

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin-4 acetate (Exenatide acetate) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin-4 acetate mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin-4 acetate inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin-4 acetate reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin-4 acetate can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

55

Linsitinib

55 Cited Publications

Cat. No.: HY-10191

CAS No.: 867160-71-2

Purity: 99.87%

Synonyms: OSI-906

Target:

IGF-1R Insulin Receptor

Research Areas:

Endocrinology Cancer

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC₅₀s of 35 and 75 nM, respectively .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide

53 Cited Publications

Cat. No.: HY-114118

CAS No.: 910463-68-2

Purity: 99.84%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide acetate

53 Cited Publications

Cat. No.: HY-114118B

CAS No.: 1997361-85-9

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

53

Semaglutide TFA

53 Cited Publications

Cat. No.: HY-114118A

Purity: 99.92%

Target:

GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:

Neurological Disease Metabolic Disease Cancer

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

46

Exendin(9-39) amide

46 Cited Publications

Cat. No.: HY-P0264

CAS No.: 133514-43-9

Synonyms: Avexitide

Target:

GLP Receptor

Exendin (9-39) amide (Avexitide) is a competitive GLP-1R antagonist. Exendin (9-39) amide blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide can be used in research on type 2 diabetes and type 1 diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

46

Exendin(9-39) amide acetate

46 Cited Publications

Cat. No.: HY-P0264A

CAS No.: 2051593-46-3

Synonyms: Avexitide acetate

Target:

GLP Receptor

Research Areas:

Metabolic Disease Inflammation/Immunology

Exendin (9-39) amide acetate (Avexitide acetate) is a competitive GLP-1R antagonist. Exendin (9-39) amide acetate blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide acetate abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide acetate can be used in research on type 2 diabetes and type 1 diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

43

Liraglutide TFA

43 Cited Publications

Cat. No.: HY-P0014B

Target:

GLP Receptor

Research Areas:

Metabolic Disease

Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

35

NCT-503

35 Cited Publications

Cat. No.: HY-101966

CAS No.: 1916571-90-8

Purity: 99.69%

Target:

Phosphoglycerate Dehydrogenase (PHGDH)

Research Areas:

Metabolic Disease Cancer

NCT-503 is a blood-brain barrier-permeable, non-competitive PHGDH inhibitor with an IC₅₀ of 2.5 μM against human PHGDH. NCT-503 reduces glucose-derived serine production and the incorporation of one-carbon units into nucleotides without decreasing PHGDH protein expression. NCT-503 prevents high selenium-induced insulin resistance in mice by regulating blood glucose and insulin levels and improving glucose tolerance, and also inhibits the growth of tumors overexpressing PHGDH. NCT-503 can be used in research related to insulin resistance and breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

32

Picropodophyllin

32 Cited Publications

Cat. No.: HY-15494

CAS No.: 477-47-4

Purity: 99.85%

Synonyms: AXL1717; Picropodophyllotoxin; PPP

Category:

Lignans 500 - Internal Server Error | MedChemExpress

country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Cart

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.